Drugs.com - FDA MedWatch Alerts

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...

May 12, 2025 - 10:14
 0
Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis
Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...
Read More

Tags:

Previous Article

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of R...

Next Article

Buy-herbal.com Issues Voluntary Nationwide Recall of Nhan Sam Tuyet Lien Truy Ph...

Related Posts

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid Hyaluronic Due to the Presence of Diclofenac and Omeprazole

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid ...

May 12, 2025  0

Public Safety Notification on Amniotic Fluid Eyedrops

Public Safety Notification on Amniotic Fluid Eyedrops

May 12, 2025  0

Health Fixer Issues Voluntary Nationwide Recall of Male Ultra, Malextra, Electro Buzz, Ultra Armor and Male Ultra Pro

Health Fixer Issues Voluntary Nationwide Recall of Male...

May 12, 2025  0